Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LOGC

LogicBio Therapeutics (LOGC) Stock Price, News & Analysis

LogicBio Therapeutics logo

About LogicBio Therapeutics Stock (NASDAQ:LOGC)

Advanced Chart

Key Stats

Today's Range
$7.10
$7.45
50-Day Range
$2.04
$2.07
52-Week Range
$0.26
$3.77
Volume
51,711 shs
Average Volume
168,718 shs
Market Capitalization
$192.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

LogicBio Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

LOGC MarketRank™: 

LogicBio Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 178th out of 210 stocks in the retail/wholesale sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for LogicBio Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LogicBio Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LogicBio Therapeutics is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    LogicBio Therapeutics has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.23% of the outstanding shares of LogicBio Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently decreased by 5.99%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    LogicBio Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LogicBio Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.23% of the outstanding shares of LogicBio Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    LogicBio Therapeutics has a short interest ratio ("days to cover") of 4.7.
  • Change versus previous month

    Short interest in LogicBio Therapeutics has recently decreased by 5.99%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for LogicBio Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    Only 6 people have searched for LOGC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of LogicBio Therapeutics is held by insiders.

  • Percentage Held by Institutions

    46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LogicBio Therapeutics' insider trading history.
Receive LOGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LOGC Stock News Headlines

ContextLogic Holdings Completes Corporate Reorganization
Man Who Called Nvidia at $1.10 Says Buy This Now...
In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.
See More Headlines

LOGC Stock Analysis - Frequently Asked Questions

LogicBio Therapeutics, Inc. (NASDAQ:LOGC) issued its earnings results on Friday, May, 9th. The company reported ($0.27) earnings per share for the quarter. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 81.98% and a negative net margin of 141.03%.
Read the conference call transcript
.

LogicBio Therapeutics (LOGC) raised $77 million in an IPO on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair served as the underwriters for the IPO and Chardan was co-manager.

LogicBio Therapeutics' top institutional investors include Simplex Trading LLC.
View institutional ownership trends
.

Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB).

Company Calendar

Last Earnings
5/09/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Catalog & mail - order houses
Sub-Industry
N/A
Current Symbol
NASDAQ:LOGC
CIK
1664106
Fax
N/A
Employees
62
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$317 million
Net Margins
-141.03%
Pretax Margin
-141.67%
Return on Equity
-81.98%
Return on Assets
-52.13%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
31.60
Quick Ratio
31.60

Sales & Book Value

Annual Sales
$287 million
Price / Sales
0.68
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.96 per share
Price / Book
0.83

Miscellaneous

Outstanding Shares
26,280,000
Free Float
24,156,000
Market Cap
$194.47 million
Optionable
Optionable
Beta
2.06

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:LOGC) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners